|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
JB Weinberg, DL Sauls, MA Misukonis and DC Shugars
Department of Medicine, VA Medical Center, Durham, NC 27705, USA.
Various cobalamins act as important enzyme cofactors and modulate cellular
function. We investigated cobalamins for their abilities to modify
productive human immunodeficiency virus-1 (HIV-1) infection of
hematopoietic cells in vitro. We show that hydroxocobalamin (OH-Cbl),
methylcobalamin (Me-Cbl), and adenosylcobalamin Ado-Cbl (Ado-Cbl) inhibit
HIV-1 infection of normal human blood monocytes and lymphocytes. The
inhibitory effects were noted when analyzing the monocytotropic strains
HIV-1-BaL and HIV-1-ADA as well as the lymphocytotropic strain HIV-1-LAI.
Cobalamins did not modify binding of gp120 to CD4 or block early steps in
viral life cycle, inhibit reverse transcriptase, inhibit induction of HIV-1
expression from cells with established or latent infection, or modify
monocyte interferon-alpha production. Because of the ability to achieve
high blood and tissue levels of cobalamins in vivo and the general lack of
toxicity, cobalamins should be considered as potentially useful agents for
the treatment of HIV-1 infection.
This article has been cited by other articles:
| |||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 1995 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
